Surgical Excision for Refractory Plantar Warts
Surgical excision is NOT recommended as routine treatment for refractory plantar warts due to lack of high-quality evidence, risk of scarring, and availability of safer alternatives, but when unavoidable in severe cases, perform radical excision with immediate split-thickness skin grafting followed by adjunctive hyperthermia (44°C foot soaks for 30 minutes daily). 1, 2
Why Surgery is Generally Avoided
The British Association of Dermatologists guidelines classify surgical interventions (curettage, cautery, CO2 laser) as Strength of Recommendation D - the lowest grade - noting "there are no high-quality studies published on the effectiveness of surgical treatments" despite their widespread use 1. This reflects the fundamental problem: surgery for plantar warts lacks robust evidence and carries significant risks.
Key Concerns with Surgical Excision:
- Scarring risk: Particularly problematic on weight-bearing surfaces where scars can cause chronic pain
- High recurrence rates: One case series showed relapse was "more common in warts that occurred at weight-bearing sites" 1
- No proven superiority: Recent cohort data shows surgery reduces treatment time by ~50% (22 vs 70 days) but doesn't address long-term recurrence 3
When Surgery Becomes Necessary
Surgery should be reserved for:
- Severe functional impairment (inability to walk, progressive ulceration)
- Immunocompromised patients with decade-long resistance to all conservative measures
- Concern for malignant transformation (requires histological confirmation)
Recommended Surgical Technique (When Unavoidable)
Based on the highest quality recent evidence 2:
Two-Stage Approach:
Stage 1: Radical Excision
- Perform complete excision of all wart tissue with clear margins
- Apply negative-pressure wound therapy to prepare wound bed
- Send tissue for histopathology to rule out malignancy
Stage 2: Immediate Reconstruction
- Apply split-thickness skin graft once wound bed is optimized
- Avoid primary closure or secondary intention healing alone (increases recurrence risk)
Critical Technical Points:
- "Radical" excision is key - incomplete removal leads to recurrence
- Immediate grafting provides better outcomes than delayed closure
- Avoid surgery on neuropathic feet or areas of poor healing 1
Essential Postoperative Care
Adjunctive hyperthermia is crucial for preventing recurrence:
- Daily foot soaks at 44°C for 30 minutes starting after graft healing 2
- This regimen achieved complete resolution with no recurrence at 6 months in an immunocompromised patient 2
- Hyperthermia alone (without surgery) shows 54% cure rates in trials 1, making it a valuable adjunct
Standard Wound Care:
- Protect graft site until fully healed
- Avoid weight-bearing as directed
- Monitor for infection, graft failure, or recurrence
Better Alternatives to Consider First
Before resorting to surgery, the guidelines strongly recommend 1:
For Plantar Warts (in order of evidence strength):
- Salicylic acid 20-30% after adequate paring, up to 6 months (Strength A)
- Cryotherapy fortnightly for 3-4 months (Strength B) - though recent trials show only 14-30% cure rates for plantar warts 1
- Intralesional bleomycin 0.1-1 mg/mL solution, 1-3 treatments (Strength B) - recent case reports show rapid resolution even in mosaic variants 4
- Pulsed-dye laser after paring/SA pretreatment, 2-4 treatments at 7-10 J/cm² (Strength C)
- Contact immunotherapy with DPC or SADBE (Strength C)
Common Pitfalls to Avoid
- Don't use surgery as first-line treatment - the evidence doesn't support it and scarring on weight-bearing surfaces causes permanent morbidity
- Don't perform simple curettage or cautery - these have even less evidence and higher recurrence rates
- Don't skip adjunctive hyperthermia - the surgical case that achieved cure used this critical postoperative component 2
- Don't operate without histology - especially in immunocompromised patients where malignant transformation risk is elevated
The Evidence Gap
The most recent surgical case report 2 from 2025 represents the highest quality evidence for surgical technique, but it's still just a single case in an immunocompromised patient. The 2026 report 5 claiming surgery as "first-line treatment" contradicts established guidelines and lacks supporting data. The 2025 cohort study 3 showing faster healing times doesn't address the critical outcome of long-term recurrence rates.
The guideline position remains clear: surgery is Strength D recommendation, reserved for exceptional circumstances when conservative measures have truly failed. 1